Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage

Intravitreal Aflibercept Injection With Panretinal Photocoagulation Versus Early Vitrectomy for Diabetic Vitreous Hemorrhage

Prospective study comparing efficacy and safety of intravitreal aflibercept injection and panretinal photocoagulation to early vitrectomy for patients with diabetic vitreous hemorrhage.

Selected patients were divided into two groups, Group I for whom intravitreal aflibercept injection followed by panretinal photocoagulation was done and group II for whom early vitrectomy was done.

Inclusion Criteria:

• Age above 18 years.
• Any sex.
• Type Ι or ΙΙ DM,
• recent diabetic VH which is causing vision impairment, precluding complete PRP and needing treatment.
• BCVA is less than 20/70 (log MAR BCVA 0.6) and better than 20/1000 (log MAR BCVA 1.7).

Exclusion Criteria:

• Tractional retinal detachment.
• Previous PRP.
• History of anti VEGF therapy within the past two months.
• Neovascular glaucoma
• Subhyaloid hemorrhage.
• Vitreomacular traction.
• Diabetic macular edema .
• Patients with systemic contraindications for anti VEGF or unstable medical conditions as uncontrolled hypertension (persistently above 180/110 mmhg) or recent thromboembolic event within the past six months.